Early detection of COVID-19 with Third Generation Assay

Double Antigen Assay for IgM + IgG + IgA Detection

Coviscreen™

Early Detection • High Sensitivity • High Specificity
Coviscreen™ Rapid Double Antigen Screening test for the detection of IgM/IgG/IgA antibodies to COVID-19 in human serum/plasma/whole blood

Coronavirus, was initially named as the 2019- novel coronavirus (SARS CoV 2) on January 2020 by World Health Organization (WHO). WHO officially named the disease as coronavirus disease 2019 i.e. COVID-19. Transmission occurs primarily via respiratory droplets from coughs and sneezes within a range of about 1.8 metres (6 ft). Indirect contact via contaminated surfaces is another cause of infection.

In densely populated demography, social isolation of the people is the only way to break the infection chain of COVID-19 infection. So, mass level testing plays a critical role to identify infected and possible infected people and isolate them to break the transmission chain of this contagious disease to stop this pandemic.

During the COVID-19 infection, various studies have shown that IgM and IgG class of antibodies can be detected almost simultaneously in the early phase of infection. There seems to be a very strong evidence that the measurement of IgA levels in patients would be of great value in the diagnosis of the SARS-CoV-2 infection. Therefore detection of total antibodies (IgA+IgM+IgG) ensures sensitive detection of the infection that is important for epidemiological screening.

Coviscreen™ is rapid double antigen screening test for detection of Total antibodies (IgA+IgM+IgG) to COVID-19 in human serum/plasma and whole blood.

**FEATURES**
- Double Antigen Sandwich Assay.
- Recombinant antigen used in both capture and tracer part.
- Finger-prick whole blood and/or serum/plasma or venous whole blood can be used.
- Well optimized assay.

**BENEFITS**
- Detection of total antibodies (IgA+IgM+IgG) ensures early detection.
- Ensure specific detection and timely isolation of the infected person.
- Facilitates mass testing at the patient site, and also in laboratory setup.
- Standardised test, suitable for all types of demography.
- Reliable performance.

**INTERPRETATION OF RESULT**

**TEST PROCEDURE**

**STEP 1**
- Disperse two drops or 20 µl sample into specimen port (A).

**STEP 2**
- Dispense four drops of Buffer into buffer port (B).

**STEP 3**
- Read the results at the end of 20 Minutes. Do not read the results beyond 30 Minutes.

**For further information contact:**
TULIP DIAGNOSTICS (P) LTD.
Gitanjali, Tulip Block, Dr. Antonio do Rego Bagh, Alto Santacruz, Bavmobil Complex Post Office, Goa - 403 202, INDIA.
Tel.: +91 832 2458546-50 Fax: +91 832 2458544 E-mail: sales@tulipgroup.com Website: www.tulipgroup.com

---

**Source References:**
6. ISO 13485